Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
AN2 Therapeutics reported financial results for the third quarter of 2026, highlighting a net loss of $11.4 million and a cash position of $51.4 million. The company is advancing its clinical pipeline, including the expected year-end enrollment initiation for its Phase 2 study of epetraborole in polycythemia vera and the selection of a new development candidate for hypophosphatasia.
Term
Q3 2026
“The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform. With FDA IND clearance for epetraborole in polycythemia vera, we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities.”
Eric Easom, Co-Founder, Chairman, President and CEO
“Beyond our clinical stage pipeline, the selection of AN2-504661 for HPP as our second development candidate this year, further demonstrates the productivity of our research organization and the potential of our boron chemistry platform to generate differentiated therapies across multiple disease areas.”
Eric Easom, Co-Founder, Chairman, President and CEO
Immunovant reported a net loss of $97.2 million for the quarter ended September 30, 2026, compared to $126.5 million in the prior year period. The company maintained a strong liquidity position with $722.3 million in cash and cash equivalents, while research and development expenses remained the primary driver of operating costs at $85.0 million for the quarter.
Tonix Pharmaceuticals reported Q3 2026 financial results, highlighted by $15 million in net sales for TONMYA, representing a 37% increase over the prior quarter. The company expanded its sales force to 150 representatives and secured major managed Medicare agreements covering an additional 30 million lives. As of September 30, 2026, the company held approximately $163 million in cash and cash equivalents.
Term
Q3 2026
“We delivered another strong quarter for TONMYA, with net sales up 37% over the second quarter. Total prescriptions, new prescriptions, and refills also increased. Payer access expanded to include two commercial group purchasing organization (GPO) agreements, two managed Medicare agreements, and Medicaid access in almost every state.”
Seth Lederman, M.D., President and Chief Executive Officer
“In addition to TONMYA’s growth, we are focused on our core clinical priorities. Our priorities include advancing TNX-102 SL in major depressive disorder (MDD), TNX-4800 for Lyme disease prevention, and the investigator-initiated study of TNX-1500 (mosdaprubart) to prevent kidney transplant rejection.”
Seth Lederman, M.D., President and Chief Executive Officer
Ocular Therapeutix reported a decrease in cash and cash equivalents to $530.6 million as of September 30, 2026, compared to $737.1 million at year-end 2025. Total assets decreased to $605.6 million, while total liabilities increased slightly to $164.7 million. The company is currently focused on Phase 3 clinical trials for AXPAXLI in wet AMD and NPDR.
Roivant Sciences reported financial results for its second fiscal quarter ended September 30, 2026, highlighted by $31.0 million in net product revenue from the first five weeks of the LISRAYA launch. The company also announced positive clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib in non-infectious uveitis, ending the period with $4.2 billion in cash and marketable securities.
Term
Q2 2026
“This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand.”
Matt Gline, CEO of Roivant
“Today we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose met the primary endpoint in Period 2, and the broader data support its potential to maintain and deepen responses in patients who have failed multiple advanced therapies and who are in need of new options.”
Aura Biosciences reported a significant increase in net loss to $111.4 million for the nine months ended September 30, 2026, driven by rising R&D and G&A expenses. Despite the loss, the company strengthened its balance sheet through a follow-on offering, ending the period with $303.1 million in current assets compared to $149.7 million at the end of 2025.
Powerfleet reported record second quarter fiscal 2027 revenue of $115.7 million, representing 4% sequential growth. The company also announced it has agreed in principle to a device financing facility with Rand Merchant Bank to support its South African National Treasury contract and hardware-as-a-service model.
Term
Q2 2027
“Q2 results demonstrate disciplined execution against our plan, with record revenue of $115.7 million and sequential margin improvement. Continued momentum across three differentiated growth engines - On-Site, AI Video, and IoT & Connected Services, combined with our major South African contract progressing ahead of our original expectations, reinforces that we are on track to deliver on our full-year objectives.”
Steve Towe, CEO of Powerfleet
“Services revenue grew 7% year-over-year, underscoring the strength of our services-led business. The device financing facility is designed to fund our largest growth opportunity as it scales. We remain on track to deliver our full-year guidance and targeted exit run-rate of $495 million and 27% EBITDA margins heading into next fiscal year.”
Paul Lalljie, President and Chief Financial Officer of Powerfleet
Tango Therapeutics reported third quarter 2026 financial results, highlighting a strong cash position of $977.5 million. The company announced plans to initiate a pivotal Phase 3 study of vopimetostat plus daraxonrasib for front-line pancreatic cancer in the first half of 2027 following positive Phase 1/2 data.
“In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer. This progress is rooted first in the data. Last month at ESMO, we shared promising data from the combination of vopimetostat plus daraxonrasib that reinforced the potential of this program to raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer.”
Malte Peters, MD, President and Chief Executive Officer of Tango
Superior Group of Companies reported Q3 2026 net sales of $146.0 million, a 5% increase year-over-year, while net income remained essentially flat at $2.6 million. The company tightened its full-year 2026 outlook, raising the lower end of its revenue and adjusted EPS guidance ranges. Management highlighted growth in Branded Products and Contact Centers segments despite strategic charges in the Healthcare Apparel business.
Term
Q3 2026
“We drove solid overall top line growth from continued momentum in our Branded Products and Contact Centers segments. New leadership in Healthcare Apparel continues to execute toward a more focused product strategy to improve margins and reduce working capital requirements in the quarters ahead. On a consolidated basis, we were able to hold EPS essentially flat versus the prior year quarter despite incremental charges associated with our strategic shift in Healthcare Apparel.”
Tango Therapeutics is a precision oncology company that remains in the clinical development stage with no approved products or revenue from sales. As of November 2, 2026, the company had 169,455,160 shares of common stock outstanding and continues to anticipate significant net losses as it advances its clinical programs, including a planned registrational trial for vopimetostat in 2027.
Immunovant reported financial results for its fiscal second quarter ended September 30, 2026, and announced positive topline data from a potentially registrational trial of IMVT-1402 in rheumatoid arthritis. The company ended the quarter with $722.3 million in cash and cash equivalents, which it expects will fund operations into 2028.
Ocular Therapeutix reported Q3 2026 financial results, highlighting a cash position of $530.6 million and an expected runway into 2028. The company remains on track to submit its NDA for AXPAXLI in wet AMD during Q4 2026 following a positive pre-NDA meeting with the FDA in September.
Term
Q3 2026
“2026 has been a transformational year for Ocular Therapeutix and we are in a strong position as we prepare to submit our NDA for AXPAXLI in wet AMD under the 505(b)(2) regulatory pathway. Frequent injections define today’s wet AMD treatment experience, and we believe AXPAXLI has the transformative potential to drastically reduce the burden on patients and caregivers.”
Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix
Hain Celestial reported fiscal first quarter 2027 results with net sales of $260 million, a 29% year-over-year decrease primarily driven by divestitures and brand exits. The company also announced it received final regulatory approvals for the sale of its International business to AURELIUS, though it missed a credit agreement amendment deadline and remains in discussions to complete the deal.
Term
Q1 2027
“During the first quarter, we made progress on our strategic actions to realign our cost structure, drive productivity, and improve our commercial and innovation capabilities. We saw our gross margin improve meaningfully year over year, reflecting progress on both our commercial and portfolio actions. We remain focused on simplifying our operating model and creating a stronger go-forward Hain.”
Alison Lewis, President and CEO
“Receiving the final required regulatory approvals is an important step toward completing the sale of our International business. We remain in discussions with our lenders regarding our capital structure and with AURELIUS regarding a path forward for the transaction. If completed, the International sale would allow us to reduce debt and create a more focused North America business with strong brands in attractive categories.”
Foghorn Therapeutics reported a significant increase in collaboration revenue to $83.5 million for the third quarter of 2026, resulting in a net income of $58.2 million compared to a net loss in the prior year. The company also improved its stockholders' deficit from $108.5 million at the end of 2025 to $14.1 million as of September 30, 2026.
CEVA reported Q3 2026 total revenues of $29.1 million, driven by record AI licensing revenues and 18% sequential growth in royalty revenues. The company highlighted a multi-year smartphone royalty growth opportunity through 2027 resulting from the ramp of internally developed modems at a major U.S. customer.
Term
Q3 2026
“We continued to grow our business in the third quarter, with 18% sequential royalty revenue growth and Ceva-powered device shipments matching our all-time quarterly record. In licensing, we achieved our highest-ever AI licensing revenues and expanded our relationships with three of our highest-volume connectivity customers, building a broader base of potential future royalty-generating products.”
Amir Panush, Chief Executive Officer of Ceva
“Royalty revenues grew 18% sequentially, led by the ramp of internally developed modems at a major U.S. customer and continued strength in broad-based IoT and connectivity, partially offset by memory-related softness in compute-intensive consumer devices.”
Affiliated Managers Group reported Q3 2026 financial results with record assets under management of $974 billion and net client cash inflows of $21 billion. The company achieved Economic EPS of $9.50, a 56% increase year-over-year, and repurchased $400 million of common stock during the quarter.
Term
Q3 2026
“AMG continues to deliver outstanding results in 2026, with year-over-year growth in Economic earnings per share of 56% for both the quarter and the year-to-date period. Net client cash flows of approximately $21 billion in the quarter, and approximately $56 billion in the year to date, reflect ongoing strength in alternative strategies, which generated record net inflows in the quarter and the last nine months of more than $31 billion and $89 billion, respectively.”
Jay C. Horgen, President and Chief Executive Officer
“Disciplined capital allocation is fundamental to our strategy; we seek to create meaningful incremental value over time by investing our capital in the areas of highest growth and return. In the quarter, we deployed $400 million into share repurchases, bringing year-to-date repurchases to $775 million, highlighting both our capital allocation discipline and our conviction in the long-term value of our business.”
Jay C. Horgen, President and Chief Executive Officer
Kamada Ltd. reported record financial results for the first nine months of 2026, with total revenues increasing 12% to $152.2 million and net income rising 29% to $21.4 million. Based on strong performance, the company increased its 2026 annual revenue guidance to $205-$208 million and declared a cash dividend of $0.14 per share.
Foghorn Therapeutics reported Q3 2026 financial results, highlighted by a significant increase in collaboration revenue to $83.5 million due to a cumulative catch-up adjustment. The company reported a net income of $44.5 million for the quarter and maintains a cash runway into the second half of 2029 to support its oncology and immunology pipelines.
“Our focus is on advancing our wholly owned portfolio, including our novel, oral I&I program in IBD, with potential for first-in-human trials by the end of 2027, and our Selective EP300 degrader which has an IND targeted for next year. We are also advancing a novel induced-proximity approach with the potential to deliver antibody-like efficacy against high-value secreted and transmembrane proteins through small molecules. With cash runway into the second half of 2029, we are well positioned to deliver on this strategy.”
Adrian Gottschalk, President and Chief Executive Officer
Keurig Dr Pepper Inc. reported a significant increase in net sales to $7,344 million for the third quarter of 2026, driven largely by the acquisition of JDE Peet's. While net income attributable to KDP rose to $882 million for the quarter, the company also recorded a $400 million gain from the sale of an equity method investment (Chobani).
Select Water Solutions reported Q3 2026 consolidated revenue of $412 million, a 28% increase year-over-year, and net income of $23 million. The company achieved record Water Infrastructure revenue of $110 million and completed the divestment of a majority interest in Peak Rentals during the quarter.
Term
Q3 2026
“During the third quarter of 2026, we delivered consolidated revenue and gross profit growth, resulting in $23 million of net income and $93 million of Adjusted EBITDA. The third quarter was a strong quarter for Select across all three operating segments, with our Water Infrastructure segment producing another quarter of record revenue and gross profit in the period.”
John Schmitz, Chairman of the Board, President and CEO
“During the third quarter of 2026, we increased total produced water volumes handled to 1.7 million barrels per day, an increase of more than 30% relative to the third quarter of 2025. These volume gains drove accretive financial contributions, resulting in Water Infrastructure segment revenues growing by 40% on a year-over-year basis to a record level of $110 million for the third quarter of 2026.”
John Schmitz, Chairman of the Board, President and CEO
Aura Biosciences reported Q3 2026 financial results and provided a clinical update on its Phase 3 CoMpass trial for bel-sar, which remains on track for topline data in 2H 2027. The company also established a new manufacturing relationship with a CDMO to secure designated capacity for bel-sar and confirmed its cash runway extends into the first half of 2029.
“During the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development. With all treatment visits completed in the CoMpass trial, our team is focused on ensuring excellence in all elements of the bel-sar program as we advance toward topline pivotal data in the second half of next year and position bel-sar as the first potential vision-preserving front-line therapy for early choroidal melanoma.”
Natalie Holles, Chief Executive Officer of Aura Biosciences
“We are very pleased to enter this new CDMO relationship, which we believe positions bel-sar for regulatory and commercial success as we advance toward topline data and completion of the CoMpass study. Designated capacity is intended to provide us with long-term control over our production scheduling, and we look forward to working with our new partner to advance this important element of the bel-sar program.”
Susan Abu-Absi, Ph.D., Chief Operating Officer of Aura Biosciences
Village Farms International reported record Q3 2026 cannabis revenues of $55 million, contributing to consolidated net sales of $67 million. The company achieved its sixth consecutive quarter of positive net income ($10 million) and ended the period with $80 million in cash. Management highlighted strong international export growth and plans to operationalize a 30-acre greenhouse in Texas for U.S. market entry.
Term
Q3 2026
“Our third quarter results were driven by record cannabis revenues of $55 million and approximately 43% of cannabis sales from some of the world’s most attractive and fastest growing international markets. We also delivered our sixth consecutive quarter of positive net income and EPS, clearly demonstrating the strength of our sustainably profitable and expanding global cannabis enterprise.”
Michael DeGiglio, President and Chief Executive Officer
“We’re pleased to report that our Phase II Netherlands facility is now fully planted and expected to begin contributing to stronger sales growth during Q4 and throughout 2027. Our Delta 2 expansion remains on track to reach its full production capacity by the middle of next year, positioning us for continued long-term organic sales growth through calendar year 2028.”
Michael DeGiglio, President and Chief Executive Officer
TG Therapeutics reported Q3 2026 total global revenue of $259.9 million, driven by $232.6 million in U.S. net product revenue for BRIUMVI. The company raised its full-year 2026 total revenue guidance to approximately $1 billion and highlighted positive Phase 3 data for a simplified BRIUMVI initiation regimen.
Term
Q3 2026
“With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI.”
Michael S. Weiss, Chairman and Chief Executive Officer
“Our increased full-year revenue guidance reflects the continued strength of our commercial business, while the approximately $100 million of shares repurchased during the quarter underscores our confidence in TG's long-term value.”
Michael S. Weiss, Chairman and Chief Executive Officer
Editas Medicine reported Q3 2026 financial results, highlighting a cash runway extending into the second half of 2028. The company received regulatory approval to initiate its Phase 1/2 Strive study for EDIT-401 in Australia and triggered a milestone payment from Bristol Myers Squibb following the acceptance of a second IND/CTA for their CAR T collaboration.
Term
Q3 2026
“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic.”
Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer
Virtus Investment Partners reported a decrease in total revenues to $197.6 million for the third quarter of 2026, down from $216.4 million in the prior year, primarily due to lower investment management fees. Net income attributable to the company for the nine months ended September 30, 2026, was $74.5 million, compared to $102.9 million in 2025. The company also completed a business acquisition during the period, resulting in a significant increase in intangible assets and goodwill.
GCM Grosvenor reported third quarter 2026 financial results, highlighted by a 17% year-over-year increase in GAAP net income and a 15% increase in fee-related earnings. The company's Board of Directors also approved a quarterly dividend of $0.12 per share and noted that $54.1 million remains available under its existing $255 million share repurchase authorization.
Praxis Precision Medicines reported third quarter 2026 financial results, highlighting a strong cash position of $1.3 billion to support operations into 2028. The company is preparing for two potential commercial launches with FDA PDUFA dates for relutrigine on December 27, 2026, and ulixacaltamide on January 29, 2027. Management is currently hiring a field sales force and expects topline results from the EMERALD study in the fourth quarter of 2026.
Term
Q3 2026
“We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a commercial CNS company. Our teams are working to bring relutrigine and ulixacaltamide to patients who need new options. The relutrigine team is fully hired, and we expect the ulixacaltamide sales force to be in place this quarter. We continue to advance our broader pipeline, with EMERALD and EMBRAVE3 progressing toward important readouts. We look forward to discussing our commercial strategies, launch readiness and pipeline at our Investor Day later this week.”
Marcio Souza, president and chief executive officer
Virtus Investment Partners reported Q3 2026 financial results with GAAP revenue of $197.6 million and diluted EPS of $3.26. Assets under management ended the period at $141.4 billion, a 16% decrease year-over-year, driven by market performance and net outflows of $6.1 billion.
Turn Therapeutics Inc. reported a net loss of $13.05 million for the nine months ended September 30, 2026, compared to $3.47 million in the prior year, driven largely by a $5.99 million loss from the change in fair value of derivative liabilities. The company significantly increased its cash position to $10.36 million following proceeds from the Avenue Capital Loan Agreement and common stock issuances.
Via Transportation reported revenue of $143.5 million for the third quarter of 2026, a 31% increase year-over-year, while narrowing its quarterly net loss to $18.8 million compared to $36.9 million in 2025. The company's cash position decreased to $324.1 million as of September 30, 2026, primarily due to $46.4 million in net cash used in operating activities during the first nine months of the year.